Estrogen receptor alpha; Estrogen receptor beta (ERα; ERβ)

Estrogen receptor alpha and estrogen receptor beta are two distinct but closely related ligand-activated nuclear receptors that mediate the physiological and pathological effects of estrogens in the body[1][2][4][7][9]. They are encoded by separate genes—ESR1 (for ERα) on chromosome 6 and ESR2 (for ERβ) on chromosome 14—and function as transcription factors upon binding estrogen or other ligands, regulating gene expression by interacting with estrogen response elements in DNA[2][4]. ERα and ERβ can form homo- or heterodimers, and while both receptors modulate growth, differentiation, and homeostasis in reproductive and non-reproductive tissues, they often exhibit different, sometimes opposing, effects depending on tissue context and specific ligands[1][7]. These receptors play essential roles in normal physiology (e.g., female reproductive system, bone, cardiovascular health, brain), and are key therapeutic targets in diseases such as hormone-dependent cancers, osteoporosis, and metabolic diseases. Drug modulation of ERα and ERβ using agonists, antagonists, or selective modulators is a major strategy in endocrine therapies, especially for breast cancer[3][9]. Their expression status is a fundamental biomarker in oncology, particularly for guiding breast cancer therapy[3][9].

Other names

Estradiol receptor alphaEstradiol receptor betaER alphaER betaESR1 (gene for ERα)ESR2 (gene for ERβ)

Antagonism (blocks estrogen activity, e.g., tamoxifen, fulvestrant); Agonism (mimics estrogen, e.g., estradiol); Selective estrogen receptor modulation (SERMs, e.g., raloxifene, tamoxifen); Downregulation/degradation of estrogen receptor (e.g., fulvestrant)